584 related articles for article (PubMed ID: 20206975)
1. Implications of serum bone turnover markers in prostate cancer patients with bone metastasis.
Kamiya N; Suzuki H; Yano M; Endo T; Takano M; Komaru A; Kawamura K; Sekita N; Imamoto T; Ichikawa T
Urology; 2010 Jun; 75(6):1446-51. PubMed ID: 20206975
[TBL] [Abstract][Full Text] [Related]
2. Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer.
Ozu C; Nakashima J; Horiguchi Y; Oya M; Ohigashi T; Murai M
Int J Urol; 2008 May; 15(5):419-22. PubMed ID: 18452459
[TBL] [Abstract][Full Text] [Related]
3. Significance of serum osteoprotegerin and receptor activator of nuclear factor κB ligand in Japanese prostate cancer patients with bone metastasis.
Kamiya N; Suzuki H; Endo T; Takano M; Yano M; Naoi M; Kawamura K; Imamoto T; Takanami M; Ichikawa T
Int J Clin Oncol; 2011 Aug; 16(4):366-72. PubMed ID: 21327451
[TBL] [Abstract][Full Text] [Related]
4. Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer.
Noguchi M; Noda S
J Urol; 2001 Sep; 166(3):1106-10. PubMed ID: 11490307
[TBL] [Abstract][Full Text] [Related]
5. Predictors of bone metastasis in pre-treatment staging of asymptomatic treatment-naïve patients with prostate cancer.
Moslehi M; Cheki M; Salehi-Marzijarani M; Amuchastegui T; Gholamrezanezhad A
Rev Esp Med Nucl Imagen Mol; 2013; 32(5):286-9. PubMed ID: 23478119
[TBL] [Abstract][Full Text] [Related]
6. Tartrate-resistant acid phosphatase 5b activity is a useful bone marker for monitoring bone metastases in breast cancer patients after treatment.
Chung YC; Ku CH; Chao TY; Yu JC; Chen MM; Lee SH
Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):424-8. PubMed ID: 16537696
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic and prognostic validity of serum bone turnover markers in metastatic renal cell carcinoma.
Jung K; Lein M; Ringsdorf M; Roigas J; Schnorr D; Loening SA; Staack A
J Urol; 2006 Oct; 176(4 Pt 1):1326-31. PubMed ID: 16952623
[TBL] [Abstract][Full Text] [Related]
8. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications.
Jung K; Lein M; Stephan C; Von Hösslin K; Semjonow A; Sinha P; Loening SA; Schnorr D
Int J Cancer; 2004 Sep; 111(5):783-91. PubMed ID: 15252851
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic and prognostic significance of tartrate-resistant acid phosphatase type 5b in newly diagnosed prostate cancer with bone metastasis: A real-world multi-institutional study.
Yamamichi G; Kato T; Yumiba S; Tomiyama E; Koh Y; Nakano K; Matsushita M; Hayashi Y; Ishizuya Y; Watabe T; Hatano K; Kawashima A; Ujike T; Ono Y; Takada T; Takada S; Imamura R; Nonomura N; Uemura M
Int J Urol; 2023 Jan; 30(1):70-76. PubMed ID: 36305578
[TBL] [Abstract][Full Text] [Related]
10. Survival markers related to bone metastases in prostate cancer.
Salminen EK; Kallioinen MJ; Ala-Houhala MA; Vihinen PP; Tiitinen SL; Varpula M; Vahlberg TJ
Anticancer Res; 2006; 26(6C):4879-84. PubMed ID: 17214355
[TBL] [Abstract][Full Text] [Related]
11. Increases in bone turnover marker levels at an early phase after starting zoledronic acid predicts skeletal-related events in patients with prostate cancer with bone metastasis.
Izumi K; Mizokami A; Itai S; Shima T; Shigehara K; Miwa S; Maeda Y; Konaka H; Koh E; Namiki M
BJU Int; 2012 Feb; 109(3):394-400. PubMed ID: 21599822
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of serum BAP, TRACP 5b and ICTP as bone metabolic markers for bone metastasis screening in lung cancer patients.
Tang C; Liu Y; Qin H; Li X; Guo W; Li J; Wang W; Qu L; Hu H; Xu C; Zheng L; Huang Y; Liu B; Gao H; Halleen JM; Liu X
Clin Chim Acta; 2013 Nov; 426():102-7. PubMed ID: 24055775
[TBL] [Abstract][Full Text] [Related]
13. Clinical usefulness of serum carboxyterminal propeptide of type I procollagen and pyridinoline cross-linked carboxyterminal telopeptide of type I collagen in patients with prostate cancer.
Akimoto S; Akakura K; Shimazaki J
Jpn J Clin Oncol; 1996 Jun; 26(3):157-63. PubMed ID: 8656556
[TBL] [Abstract][Full Text] [Related]
14. [Measurements and clinical usefulness of carboxyterminal propeptide of type I collagen and cross-linked carboxyterminal telopeptide of type I collagen in patients with prostate cancer].
Igawa T; Sakai H; Kanetake H; Saito Y
Hinyokika Kiyo; 1999 Apr; 45(4):235-9. PubMed ID: 10363141
[TBL] [Abstract][Full Text] [Related]
15. Serum levels of PSA, ALP, ICTP, and BSP in prostate cancer patients and the significance of ROC curve in the diagnosis of prostate cancer bone metastases.
Wei RJ; Li TY; Yang XC; Jia N; Yang XL; Song HB
Genet Mol Res; 2016 Jun; 15(2):. PubMed ID: 27323113
[TBL] [Abstract][Full Text] [Related]
16. Comparison of markers of bone formation and resorption in prostate cancer patients to predict bone metastasis.
Akimoto S; Furuya Y; Akakura K; Ito H
Endocr J; 1998 Feb; 45(1):97-104. PubMed ID: 9625452
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors in metastatic prostate cancer.
Yigitbasi O; Ozturk U; Goktug HN; Gucuk A; Bakirtas H
Urol Oncol; 2011; 29(2):162-5. PubMed ID: 19450995
[TBL] [Abstract][Full Text] [Related]
18. Relationship between prostate-specific antigen, clinical stage, and degree of bone metastasis in patients with prostate cancer: comparison with prostatic acid phosphatase and alkaline phosphatase.
Akimoto S; Furuya Y; Akakura K; Shimazaki J; Ito H
Int J Urol; 1997 Nov; 4(6):572-5. PubMed ID: 9477186
[TBL] [Abstract][Full Text] [Related]
19. Analysis of biochemical bone markers as prognostic factors for survival in patients with hormone-resistant prostate cancer and bone metastases.
Petrioli R; Rossi S; Caniggia M; Pozzessere D; Messinese S; Sabatino M; Marsili S; Correale P; Salvestrini F; Manganelli A; Francini G
Urology; 2004 Feb; 63(2):321-6. PubMed ID: 14972482
[TBL] [Abstract][Full Text] [Related]
20. Serum TRACP 5b and ICTP as markers of bone metastases in breast cancer.
Korpela J; Tiitinen SL; Hiekkanen H; Halleen JM; Selander KS; Väänänen HK; Suominen P; Helenius H; Salminen E
Anticancer Res; 2006; 26(4B):3127-32. PubMed ID: 16886645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
